As this rate is lowest in the two GPOH-protocols using IFNβ as adjuvant therapy compared to other prospective studies without IFNβ, IFNβ might well have an antimetastatic effect in NPC. The gene discussed is IFNB1; the disease is nasopharyngeal carcinoma.